Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

72-week data of atacicept in IgAN accepted as a best-ranked abstract

Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation

BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61^st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.

ERA24 Presentation Details:

Free Communication Presentation – selected as a best-ranked abstract by the ERA24 Congress Paper Selection Committee
Title:	Phase 2b ORIGIN Study Open Label Extension with Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria: Week 72 Interim Analysis
Presenting Author:	Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center
Session:	FC 17 - Novel treatments of immune mediated kidney diseases
Room:	A5
Date, time:	May 25, 2024, 15:36-15:48 CEST
Focused Oral Presentation
Title:	Impact of Atacicept on Hematuria in IgA Nephropathy: Post-Hoc Analysis of the Phase 2b ORIGIN Study
Presenting Author:	Jürgen Floege, M.D., Senior Professor, Division of Nephrology and Rheumatology, University of Aachen, Germany
Session:	Glomerular, tubulo-interstitial diseases & general nephrology
Room:	Focused Oral Room 3
Date, time:	May 25, 2024, 12:00-13:15 CEST

For more information on these abstracts, please visit the 61^st ERA Congress website.